Pediatric invasive aspergillosis

Pediatric Infectious Disease Journal

Volumn 29, Issue 10, 2010, Pages 964-965

  Steinbach, William J ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antifungal; aspergillosis; galactomannan

Indexed keywords

AMPHOTERICIN A; AMPHOTERICIN B DEOXYCHOLATE; GALACTOMANNAN; ITRACONAZOLE; POSACONAZOLE; VINCRISTINE; VORICONAZOLE;

COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH RISK PATIENT; HUMAN; INVASIVE ASPERGILLOSIS; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 77957274058     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181f35eb1     Document Type: Review

References (10)

1. Maertens J, et al. Galactomannan and computed tomography-based preemptive⋯. Clin Infect Dis. 2005;41:1242-1250.
2. Walsh TJ, et al. Reduced expression of galactomannan antigenemia⋯ . In: Program and Abstracts of the 40th Annual Meeting of the Infectious Diseases Society of America. October 24-27, 2002; Chicago, IL.
3. Steinbach WJ, et al. Prospective Aspergillus galactomannan antigen testing in pediatric⋯ . Pediatr Infect Dis J. 2007;26:558-564.
4. Hayden R, et al. Galactomannan antigenemia in pediatric oncology⋯. Pediatr Infect Dis J. 2008; 27:815-819.
5. Herbrecht R, et al. Voriconazole versus amphotericin B⋯ . N Engl J Med. 2002;347:408-415.
6. Patterson TF, et al. Strategy of following voriconazole versus amphotericin B therapy⋯. Clin Infect Dis. 2005;41:1448-1452.
7. Walsh TJ, et al. Treatment of aspergillosis⋯ . Clin Infect Dis. 2008;46:327-360.
8. Steinbach WJ, et al. Review of newer antifungal⋯. Clin Infect Dis. 2003;37(suppl 3):S157-187.
9. Walsh TJ, et al. Treatment of invasive aspergillosis with posaconazole⋯. Clin Infect Dis. 2007; 44:2-12.
10. Walsh TJ, et al. Pharmacokinetics and safety of intravenous voriconazole in children⋯ . Antimicrob Agents Chemother. 2004;48:2166-2172.